Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO - The Christie Preceptorship on Lung Cancer 2024: Manchester
- Start date
- 06 Mar 2024
- End date
- 08 Mar 2024
- Location
- Manchester, United Kingdom
Learning objectives
- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies
Accreditation
The programme of this event has been accredited with 16 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- Fiona Blackhall, United Kingdom
- Raffaele Califano, United Kingdom
- Lizza Hendriks, Netherland
Supported by
